Pfizer Inc. or ACADIA Pharmaceuticals Inc.: Who Invests More in Innovation?

Pfizer's R&D spending dwarfs ACADIA's by 40x.

__timestampACADIA Pharmaceuticals Inc.Pfizer Inc.
Wednesday, January 1, 2014606020008393000000
Thursday, January 1, 2015738690007690000000
Friday, January 1, 2016992840007872000000
Sunday, January 1, 20171491890007657000000
Monday, January 1, 20181871630008006000000
Tuesday, January 1, 20192403850008650000000
Wednesday, January 1, 20203191300009405000000
Friday, January 1, 202123941500013829000000
Saturday, January 1, 202236157500011428000000
Sunday, January 1, 202335161900010679000000
Loading chart...

Unleashing insights

Innovation Investment: Pfizer vs. ACADIA Pharmaceuticals

In the competitive world of pharmaceuticals, innovation is key to staying ahead. Over the past decade, Pfizer Inc. and ACADIA Pharmaceuticals Inc. have shown contrasting approaches to research and development (R&D) investments. From 2014 to 2023, Pfizer consistently outspent ACADIA, with R&D expenses peaking at approximately $13.8 billion in 2021. In contrast, ACADIA's highest investment was around $362 million in 2022. This stark difference highlights Pfizer's commitment to innovation, spending nearly 40 times more than ACADIA on average. However, ACADIA has shown a steady increase in its R&D spending, growing by over 480% from 2014 to 2023. This trend suggests a strategic shift towards more aggressive innovation efforts. As the pharmaceutical landscape evolves, these investments will likely play a crucial role in shaping the future of both companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025